Calendar

Cloudflare’s reported Q2 2026 revenue growth and a $736.8M Q3 revenue consensus provide a credible business backdrop, but the stock fell sharply into the event: it lost roughly 15.5% from Oct. 26 to Oct. 30, including a high-volume down day. Required positive tape and estimate-upside signals are not supported.

ABNB has a small positive whisper-versus-consensus gap and recent company guidance describes strong revenue growth, but the guidance midpoint is slightly below the checked revenue consensus. The stock fell about 4.4% over five sessions, had no close above the 0.75 close-location threshold in the latest three sessions, and no confirmed 1.5x volume session; it does not qualify despite a supportive XLY tape.

EOG has upward EPS estimate revisions, a credible Q3 consensus, and a strong Oct. 30 close, but available checks did not establish positive revenue revisions or a recent >1.5x-volume accumulation day. The company has scheduled its Q3 results for Nov. 5 after close; its IR page separately lists a Nov. 6 results call.

Lumentum's September-quarter EPS estimate rose from $4.21 to $4.22 over the last month, and its prior company guidance midpoint for $1.25B revenue is in line with reported consensus; management cited accelerating AI-driven optical demand and the stock advanced sharply over the preceding five sessions. However, the late-week reversal and lack of a verified normal-volume comparator temper the setup, while valuation and execution risks remain material.

Simon has positive, though non-uniform, estimate momentum: checked consensus showed EPS up 1.74% and revenue up 3.69% over three months, and its latest reported quarter showed 96.0% occupancy, higher retailer sales, and raised full-year FFO guidance. The stock gained about 2.4% over five sessions and closed near the top of its Oct 30 range, but a normal-volume comparison was unavailable and its recent earnings history is uneven.

DVN has positive near-term estimate revisions, rising revenue expectations, four recent EPS beats per Zacks, and an official Nov. 5 reporting date; the stock also strengthened into the event. However, earnings-whisper EPS is below some consensus figures and the shares lagged the energy sector over the past month, while commodity exposure and transaction execution leave meaningful uncertainty.

Earnings Whispers reports a $1.48 whisper against $1.39 consensus, while the prior quarter had strong reported growth; however, no reliable pre-event revenue-revision, verified close-location, or volume-accumulation evidence was found for this screen, and the supplied latest close does not establish recent strength. The positive whisper alone is insufficient for qualification.

ED's reported date and consensus figures were available, and the recent close rose with XLU supportive; Con Edison had reaffirmed its 2026 adjusted EPS guidance. But no positive EPS revision, ESP, whisper, or revenue-upside signal was verified, and none of the last three checked sessions closed in the upper quarter of its range.

A pre-event Zacks article says the estimate-revision combination points toward a likely EPS beat, and recent annualized recovery expectations offer a possible cyclical catalyst. However, exact revision and current-quarter revenue consensus/upside evidence was not verifiable in the checked results, while Oct. 30 brought a high-volume 4.66% selloff and a weak close; it fails the required tape confirmation.

Live Nation has strong operating indicators ahead of the report: the latest available filing said 2026 event ticket sales were pacing 11% higher and deferred revenue reached a second-quarter record, while the stock recovered into Oct. 30 on a large-volume up day. But current-quarter revenue consensus estimates varied across checked providers and no positive EPS revision/ESP/whisper was verified; score remains below the required threshold.

The supplied Nov. 5 date conflicts with checked earnings sources: Earnings Whispers and MarketBeat indicate Nov. 4, while another estimate page shows Nov. 5 and cautions the date may move. Consensus estimates exist, but no positive revisions or required tape confirmation were established; reject on unconfirmed event date and incomplete signals.

MRNA has a modestly favorable EPS revision snapshot and a recent high-volume rebound, but the checked calendar sources describe Nov. 6 as estimated rather than company-confirmed, and no positive revenue revision or upside indicator was verified. The Oct. 22 melanoma-trial data leak coincided with a 17.57% drop and unusually high volume, leaving a volatile, event-driven tape.

Record Q2 fundraising and 20% fee-related-earnings growth, alongside a rising recent share price and several analyst target cuts, create a constructive but mixed backdrop. The checked sources support EPS and revenue consensus, but do not establish positive estimate revisions or an upside surprise signal; recent volume also falls short of a verified accumulation trigger.

Humana's primary IR estimate table showed near-flat Q3 EPS revisions and a credible consensus source provides EPS and revenue estimates, but the stock weakened into the event and underperformed the rising XLV. Medical-cost and Medicare policy uncertainty remain material, while recent tape did not confirm accumulation.

Vistra has a company-confirmed Nov. 6 report date and a strongly positive 30-day Q3 EPS revision, alongside long-term power-demand catalysts. However, shares declined about 5.4% from Oct. 26 through Oct. 30, recent closes were weak in their daily ranges, and the latest quarter missed consensus materially. Positive revisions alone do not offset the poor pre-event tape and limited recent execution evidence.

Initial coverage linked the earnings beat to a 2.77% premarket gain, but the packet's October 15 closing anchor is $65.37; the initial reaction should not be assumed to have held. News tone is positive on the beat but mixed on precast and fiscal Q1 segment guidance. No reliable post-print analyst target or estimate revisions were found at this T+1 check; social and options signals were unavailable. [Investing.com reaction](https://uk.investing.com/news/earnings/cmc-shares-rise-3-on-fourth-quarter-earnings-beat-4911845)

Mixed-to-negative immediately after earnings: trusted [AP coverage](https://apnews.com/article/a2edaf9ec297fb75ff2a4e245063ec08) reports a 3.1% October 13 share decline tied to weaker-than-expected revenue despite a profit beat. The October 15 RankAlpha anchor is $82.75, but the packet does not establish whether the initial reaction fully held or reversed. Post-print target cuts are available, though a comprehensive forward-estimate revision series is not. The pre-print $1.85 EPS and $22.15 billion revenue estimates come from a third-party article stored as an earnings document, not an official company release. Social, options, short-interest and employee metrics are unavailable; zero values above are placeholders, not measured readings.

The SEC-filed earnings release confirms stronger Q2 adjusted results and raised guidance, but the market response was mixed: AZZ gained 0.7% on October 14, then fell 5.1% on October 15 to the $130.59 anchor. Four reported post-print analyst target changes include one cut and three increases; broader forward earnings-estimate revisions remain unavailable. The zero-valued social, options, short-interest, employee and news-sentiment fields denote unavailable measurements, not neutral readings. The deterministic prior shifted from positive to neutral, so this T+3 update remains a monitoring view. [#SEC-8K-2026-10-13] [Historical prices](https://chartexchange.com/symbol/nyse-azz/historical/) [Benzinga](https://www.benzinga.com/news/26/10/62385651/azz-analysts-boost-their-forecasts-after-upbeat-q2-results)

The initial October 13 close was $377.76, down 0.2% on the day; shares then closed at $395.62 on October 14 and $406.67 on October 15, about 7.4% above the pre-release October 12 close. The rebound occurred alongside broader healthcare buying, so it should not be attributed solely to earnings. Post-print target revisions were mixed, and a dependable aggregate estimate-revision series is unavailable. Social, options, short-interest and employee readings were not supplied; zero sentiment fields denote unavailable data, not neutral readings. https://chartexchange.com/symbol/nyse-unh/historical/ https://www.benzinga.com/quote/UNH/price-targets

The official earnings release was October 6, although the scheduled follow-up names October 13. Shares fell about 3.8% on October 6, from $45.46 to $43.72, then recovered only partly to the packet's $44.32 October 15 adjusted-close anchor; price action alone does not establish why investors sold. [Historical prices](https://chartexchange.com/symbol/nasdaq-vlgea/historical/) Verified post-print analyst revisions and consensus estimates remain unavailable, so missing coverage is not a positive signal. The prior neutral thesis remains broadly intact, but the Q4 cost pressure and fiscal 2027 investment plan sharpen monitoring priorities.

Company-reported results are positive, but the tape is mixed: Goldman rose more than 4% early on October 13, then closed about 0.2% lower, according to [AP](https://apnews.com/article/a2edaf9ec297fb75ff2a4e245063ec08). [Benzinga](https://www.benzinga.com/analyst-stock-ratings/price-target/26/10/62363583/these-analysts-lower-their-forecasts-on-goldman-sachs-after-q3-results) reported RBC and KBW target cuts on October 14. The 30-day news score is a qualitative estimate; zero social, options, short-interest and employee fields denote unavailable measurements, not neutral readings. No verified broad estimate-revision series or company Q4 numerical guidance is available in the checked evidence.